Assoz.-Prof. PD Dr. Thorsten Füreder, Universitätsklinik für Innere Medizin, Wien, erklärt, welche Patienten mit Plattenepithelkarzinomen im Kopf-Hals-Bereich Pembrolizumab bekommen sollen und wodurch das EXTREME-Schema ersetzt werden könnte.

Abstracts, die in diesem Video diskutiert werden:

Rischin D et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Abstract 6000

Guigay et al. TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Abstract 6002

Ma J et al. Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial. Abstract 6003

Chen MY et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicenter randomized controlled trial. Abstract 6004

Li BT et al. Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial. Abstract 6001